DK0713495T3 - Fremgangsmåder til forstærkning af den biologiske aktivitet af chemokiner - Google Patents

Fremgangsmåder til forstærkning af den biologiske aktivitet af chemokiner

Info

Publication number
DK0713495T3
DK0713495T3 DK94920701T DK94920701T DK0713495T3 DK 0713495 T3 DK0713495 T3 DK 0713495T3 DK 94920701 T DK94920701 T DK 94920701T DK 94920701 T DK94920701 T DK 94920701T DK 0713495 T3 DK0713495 T3 DK 0713495T3
Authority
DK
Denmark
Prior art keywords
biological activity
methods
chemokines
enhancing
truncated
Prior art date
Application number
DK94920701T
Other languages
English (en)
Inventor
Louis M Pelus
Pradip Kumar Bhatnagar
Andrew Garrison King
Joanna Maria Balcarek
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DK0713495T3 publication Critical patent/DK0713495T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK94920701T 1993-06-08 1994-06-03 Fremgangsmåder til forstærkning af den biologiske aktivitet af chemokiner DK0713495T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7380093A 1993-06-08 1993-06-08
PCT/US1994/006264 WO1994029341A1 (en) 1993-06-08 1994-06-03 Methods of enhancing bioactivity of chemokines

Publications (1)

Publication Number Publication Date
DK0713495T3 true DK0713495T3 (da) 2004-03-08

Family

ID=22115875

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94920701T DK0713495T3 (da) 1993-06-08 1994-06-03 Fremgangsmåder til forstærkning af den biologiske aktivitet af chemokiner

Country Status (9)

Country Link
US (3) US6080398A (da)
EP (2) EP1378522A3 (da)
JP (1) JP4006021B2 (da)
AT (1) ATE253637T1 (da)
DE (1) DE69433301T2 (da)
DK (1) DK0713495T3 (da)
ES (1) ES2210255T3 (da)
PT (1) PT713495E (da)
WO (1) WO1994029341A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1378522A3 (en) * 1993-06-08 2004-02-04 SmithKline Beecham Corporation Methods of enhancing bioactivity of chemokines
US6447766B1 (en) * 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
AT403098B (de) * 1995-05-29 1997-11-25 Nycomed Austria Gmbh Antikörper zum nachweis und zur unterscheidung von verkürzten und nicht verkürzten formen von chemokinen
ZA968896B (en) * 1995-10-24 1997-04-24 Smithkline Beecham Corp Method of mobilizing hematopoietic stem cells
US6042821A (en) * 1995-11-21 2000-03-28 Smithkline Beecham Corporation Method of treating sepsis with chemokines
AU1020997A (en) * 1995-11-21 1997-06-11 Smithkline Beecham Corporation Method of treating sepsis
US6852508B1 (en) * 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6534626B1 (en) 1997-12-01 2003-03-18 The United States Of America As Represented By The Department Of Health & Human Services Chemokine variants
AU2002216749A1 (en) * 2000-06-30 2002-01-14 Smithkline Beecham Corporation Chemokine conjugates
CA2561171A1 (en) * 2004-03-30 2005-10-20 Amylin Pharmaceuticals, Inc. Synthetic chemokines, methods of manufacture, and uses
AU2005272653A1 (en) * 2004-08-13 2006-02-23 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
EP2015781A4 (en) * 2005-09-12 2009-12-23 Univ Johns Hopkins COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF
US20100003224A1 (en) * 2006-08-02 2010-01-07 Genzyme Corporation Combination Therapy
JP2010507567A (ja) * 2006-08-07 2010-03-11 ジェンザイム・コーポレーション 併用療法
ES2727787T3 (es) 2009-11-15 2019-10-18 Univ Indiana Res & Tech Corp Métodos para mejorar el suministro y el injerto de células madre incluida la identificación de receptores específicos de prostaglandina E2
KR102503695B1 (ko) 2013-02-28 2023-02-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 줄기세포를 동원하기 위한 방법 및 조성물
US10457683B2 (en) 2017-04-12 2019-10-29 Magenta Therapeutics Inc. Aryl hydrocarbon receptor antagonists and uses thereof
WO2019055776A2 (en) * 2017-09-14 2019-03-21 Rosser Charles COMPOSITIONS AND METHODS FOR TREATING DISEASES INVOLVING CXCL1 FUNCTION
US20190343885A1 (en) 2017-10-31 2019-11-14 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
EP3704232A1 (en) 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
BR112020011186A2 (pt) 2017-12-06 2020-11-17 Magenta Therapeutics, Inc. regimes de dosagem para a mobilização de células-tronco e progenitoras hematopoiéticas
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
WO2019136159A1 (en) 2018-01-03 2019-07-11 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
US20220401481A1 (en) 2019-11-01 2022-12-22 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
MX2022013493A (es) 2020-04-27 2023-02-22 Magenta Therapeutics Inc Metodos y composiciones para transducir celulas madre y progenitoras hematopoyeticas in vivo.
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
WO2022197776A1 (en) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703206A (en) * 1981-09-08 1997-12-30 Univ Rockefeller Macrophage inflammatory protein 2 (MIP-2)
GB8626539D0 (en) * 1986-11-06 1986-12-10 Nycomed As Peptide compounds
ZW11290A1 (en) * 1989-07-14 1990-10-31 Smithkline Beecham Corp Hemoregulatory peptides
IL96477A0 (en) * 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
PT98072B (pt) * 1990-06-22 1998-11-30 Chiron Corp Processo para a preparacao de polipeptidos contendo proteina macrofagica inflamatoria humana mip-2 alfa por metodos recombinantes e de composicoes farmaceuticas que os contem
US5154921A (en) * 1990-07-13 1992-10-13 Dana-Farber Cancer Institute, Inc. Promotion of maturation of hematopoietic progenitor cells
WO1992006196A1 (en) * 1990-09-28 1992-04-16 Cetus Oncology Corporation Gro genes, proteins, and uses thereof
EP1378522A3 (en) * 1993-06-08 2004-02-04 SmithKline Beecham Corporation Methods of enhancing bioactivity of chemokines
EP0703784B1 (en) * 1993-06-15 2002-03-06 British Biotech Pharmaceuticals Limited Release and mobilisation of haematopoietic cells
US5459128A (en) * 1993-11-12 1995-10-17 Dana-Farber Cancer Institute Human monocyte chemoattractant protein-1 (MCP-1) derivatives
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
GB9426012D0 (en) * 1994-12-22 1995-02-22 British Biotech Pharm Mobilisation of haematopoietic cells

Also Published As

Publication number Publication date
ATE253637T1 (de) 2003-11-15
JPH08511167A (ja) 1996-11-26
DE69433301D1 (de) 2003-12-11
DE69433301T2 (de) 2004-09-09
EP0713495B1 (en) 2003-11-05
PT713495E (pt) 2004-03-31
ES2210255T3 (es) 2004-07-01
EP1378522A2 (en) 2004-01-07
US6399053B1 (en) 2002-06-04
EP0713495A4 (en) 1998-06-03
US20040057925A1 (en) 2004-03-25
EP1378522A3 (en) 2004-02-04
JP4006021B2 (ja) 2007-11-14
EP0713495A1 (en) 1996-05-29
WO1994029341A1 (en) 1994-12-22
US6080398A (en) 2000-06-27

Similar Documents

Publication Publication Date Title
DK0713495T3 (da) Fremgangsmåder til forstærkning af den biologiske aktivitet af chemokiner
DE69434942D1 (de) Mehrzweckreagenzsystem zur schnellen lysierung von vollblutproben
DK0791571T3 (da) Benzoylderivater
DK0713529T3 (da) Vækst-/differentieringsfaktor af TGF-beta-familien
DE69534300D1 (de) Neues multimerisierendes reagenz
DE69009332T2 (de) Magnetisch angetriebene schwingbalkenkraftwandler.
DE69232309T4 (de) Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen
ATE213639T1 (de) Proteinreinigung
DE3878502D1 (de) Mechanismus zur daempfung von torsionsschwingungen.
ATE342911T1 (de) Synthese von nukleosiden und polynukleotiden
CA2008817A1 (en) M-csf monoclonal antibodies that recognize a neutralizing conformational epitope
DE69433400D1 (de) Neue proteine von parasitischen würmern
DK0638068T3 (da) Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
FR2709410B1 (fr) Plaque-agrafe pour ostéosynthèse.
ATE271125T1 (de) Neuartige tyrosinkinase
DE68910676T2 (de) Verwendung von Creosot als antispastischer Wirkstoff.
DE69231940D1 (de) Rekombinant DNS kodierend für eine Endochitinase
DK0585570T3 (da) Granulocytbindende antistofkonstrukter, deres fremstilling og anvendelse
ZA952125B (en) Monoclonal antibody
ATE68486T1 (de) 1-((2-fluorophenyl)(4-fluorophenyl)phenylmethyl - 1h-imidazol.
DE69000909D1 (de) Transportables brueckenteil zur ueberwindung von graeben.
DE69000908T2 (de) Leichtes transportables brueckenteil zur ueberwindung von graeben.
DK0408734T3 (da) Fremgangsmåde til rensning af streptokinaser
FR2708974B1 (fr) Système de construction de meubles pour laboratoire perfectionné.
FI956041A (fi) Kompositiot ja diagnostiset menetelmät, joissa käytetään monoklonaalisia vasta-aineita CD44V6 vastaan